Amphastar Pharmaceuticals, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $45.21M, a 15.28% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $29.49M, a 168.11% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $20.52M, a 51.15% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $4.85M, a 86.13% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2025 was $75.59M, a 11.55% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2024 was $85.46M, a 46.98% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2023 was $58.14M, a 45.69% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2022 was $39.91M, a 38.22% increase from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $45.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $100.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $29.49M 10-Q · filed 2026-05-07 | $94.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.59M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $97.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $39.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $127.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.00M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.46M 10-K · filed 2026-02-26 |
| 2024-09-30 | $34.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $58.14M 10-K · filed 2026-02-26 |
| 2023-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $76.21M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $40.71M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $8.02M 10-Q · filed 2024-05-10 | $46.70M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $18.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $39.91M 10-K · filed 2025-03-03 |
| 2022-09-30 | $14.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $35.28M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $6.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $26.88M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.23M 10-Q · filed 2023-05-09 | $26.32M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $13.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $28.87M 10-K · filed 2024-02-29 |
| 2021-09-30 | $6.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $18.83M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $5.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $17.06M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $3.78M 10-Q · filed 2022-05-10 | $17.26M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $24.43M 10-K · filed 2023-03-01 |
| 2020-09-30 | $4.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $34.81M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $34.91M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $10.95M 10-Q · filed 2021-05-07 | $30.23M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $13.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $22.29M 10-K · filed 2022-03-11 |
| 2019-09-30 | $4.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $11.12M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $14.29M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $3.02M 10-Q · filed 2020-05-11 | $20.44M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $25.05M 10-K · filed 2021-03-15 |
| 2018-09-30 | $7.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $28.41M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $7.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $28.42M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $7.62M 10-Q · filed 2019-05-10 | $30.17M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $30.75M 10-K · filed 2020-03-16 |
| 2017-09-30 | $7.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $25.70M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $8.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $18.90M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $8.20M 10-Q · filed 2018-05-10 | $13.39M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $922.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $9.91M 10-K · filed 2019-03-15 |
| 2016-09-30 | $796.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $13.16M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $3.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $15.34M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $4.72M 10-Q · filed 2017-05-10 | $13.10M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $9.87M 10-K · filed 2018-03-14 |
| 2015-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $5.55M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | |
| 2015-03-31 | $1.49M 10-Q · filed 2016-05-10 | |
| 2014-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $345.00K 10-K · filed 2017-03-15 |
| 2013-12-31 | $184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-26 | $199.00K 10-K · filed 2015-03-26 |
| 2012-12-31 | $811.00K 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |